Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1995-06-07
1998-08-18
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241921, 4241941, 42419711, 4242031, 530403, A01J 2100, A01J 1700, C07K 100
Patent
active
057955808
ABSTRACT:
This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention further relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type V which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II) and/or Group B streptococcus type V (GBS V). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.
REFERENCES:
patent: 4207414 (1980-06-01), Kasper
patent: 4324887 (1982-04-01), Kasper
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4356263 (1982-10-01), Kasper
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4902506 (1990-02-01), Anderson et al.
Dick and Beurret (1989) "Glyconjugates of Bacterial Carbohydrate Antigens -- A Survey and Consideration of Design and Preparation Factors" Conjugate Vaccines In Contrib. Microbiol. Immunol. Cruse, JM and Lewis, RE. Tr. (eds.) Basel Karger Vol.10:48:114.
Jennings, (1983) "Capsular Polysaccharrides as Human Vaccines" In Advances Carbohydrate Chemistry and Biochemistry, Vol. 41:155-207. Academic Press, Inc., NY. NY.
Paoletti (1992) Effects of Chain Length on the Immunogenecity in Rabbits of Group B Streptococcus Type III Oligosaccharride -- Tetanus Toxoid Conjugate. J. Clin. Invest. 89:203-209.
Paoletti (1992) "Group B Streptococcus Type II Polysaccharide --Tetanus Conjugate Vaccine" Infection and Immunity, vol. 60:4009-4014.
Michael R. Wessels, et al., (1989) "Isolation and Characterization of Type IV Group B Streptococcus Capsular Polysaccharide" Infection and Immunity vol. 57, No. 4:1089-1094.
Dennis L. Kasper, et al. (1983) "Immunochemical Analysis and Immunogenicity of the Type II Group B Streptococcals Capsular Polysaccharide ", J. Clin. Invest. vol. 72:260-269.
Harold J. Jennings, et al. (1982) "Structural Determination of the Capsular Polysaccharide Antigen of Type II Group B Streptococcus", The Journal of Biological Chemistry, vol. 258:1793-1798.
Lawrence C. Paoletti, et al. (1900) "An Oligosaccharide--Tetanus Toxoid Conjugate Vaccine against Type III Group B Streptococcus", The Journal of Biological Chemistry, vol. 265:18278-18283.
Ariane K. Rodewald, et al. (1992) "Neonatal Mouse Model of Group B Streptococcal Infection", The Journal of Infectious Diseases, vol. 166:635-9.
Wessels et al, J. Biol. Chem. 266(11): 6714-6719, 1991.
Ward et al, "Haemophilus influenza Vaccines" in Vaccines, Plotkin et al eds. W. B. Saunders Co. Philadelphia, 1988 pp. 300-330.
Facklam et al, "Streptococci and Aerococci" in Manual of Clinical Microbiology, Lennette et al eds. American Society for Microbiol, Wash DC 1985, pp. 154-175.
Baker et al, Reviews of Infectious Diseases 7(4): 458-467, 1985
Baker et al, New Engl. J. Med, 319 18: 1180-1185, 1988.
Sarvamangala et al, Proc. Natl. Acad. Sci. 88: 7175-7179, 1991.
Wessels et al, J Clin. Invest. 86: 1428-1433, 1990.
Boyer et al, Clinical Research 34(4): 962 A, 1986.
Jennings et al, Biochemistry, 20(16): 4511-4518, 1981.
Reuter et al, Glyconjugate J. 6: 35-44, 1989.
Jennings Harold J.
Kasper Dennis L.
Brigham and Women's Hospital, Inc.
Housel James C.
National Research Council of Canada
Shaver Jennifer
LandOfFree
Group B streptococcus type V polysaccharide-protein conjugate va does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group B streptococcus type V polysaccharide-protein conjugate va, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group B streptococcus type V polysaccharide-protein conjugate va will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1112610